$ cat ./records/gates-backed-cepi-funds-jurata-thin-film-for-needle-free-sublingu-2023.txt
Gates-Backed CEPI Funds Jurata Thin Film for Needle-Free Sublingual mRNA Vaccine Wafer
[RECORD.TXT] · cat --full
CEPI — co-founded and substantially funded by the Gates Foundation — provided up to $1.2 million to Jurata Thin Film, Inc. to develop an under-the-tongue mRNA vaccine film stable at room temperature for up to three years. The wafer encapsulates lipid nanoparticle-encapsulated mRNA in a dissolvable oral format, eliminating both needles and cold-chain requirements. CEPI described the technology as a Disease X preparedness platform and a model for expanding mRNA vaccine access in remote or infrastructure-limited regions.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards Ginkgo Bioworks Grant for Implantable Live-Cell HIV and Malaria Antibody Platform
Next →
Gates Foundation Expands Sayana Press Self-Injectable Contraceptive to 92 Countries
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.